Based on these data, we hypothesize that NSCLC patients with a tumor positive for ERCC-1 gene SNPs could be more genetically instable, could present higher mutational load, and consequently could be more responsive to PD-1 ICB when compared to subjects negative for these genetic alterations. The gene discussed is ERCC1; the disease is neoplasm.